-- Hercules Metals (BIG.V) 周三宣布，将私募配售股票的融资规模从 2320 万美元提高至 3150 万美元。 该公司通过包销私募配售方式，以每股 0.59 美元的价格向承销商出售了 3640 万股股票，筹集了 2140 万美元。 该公司还计划通过经纪商私募配售方式，以每股 0.59 美元的价格出售 1700 万股股票，筹集 1000 万美元。 Barrick Mining (ABX.TO) 拥有参与权以维持其在该公司的股份，但 Hercules 并未透露该公司是否计划参与此次配售。 所得款项将用于勘探和开发其位于爱达荷州西部、全资拥有的 Hercules 矿产项目，以及满足一般营运资金需求。 该公司股票在多伦多证券交易所创业板 (TSX Venture Exchange) 的最新报收于 0.63 美元，下跌 0.01 美元。
Price: $0.63, Change: $-0.01, Percent Change: -1.56%
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%